RCG
JUNO

Ruggie Capital Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Ruggie Capital Group’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,000
Closed -$60K – 296
2017
Q2 		$60K Buy
+2,000
New +$49.4K 0.04% 125

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ruggie Capital Group's JUNO Position: Q3 2017 in Review

Ruggie Capital Group sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2017, closing a stake of 2,000 shares — an estimated $60K sold.

Ruggie Capital Group first reported a position in JUNO in Q2 2017 and held it in 1 quarter. The position peaked at $60K in Q2 2017. 210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

  • Ruggie Capital Group reported no remaining Juno Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Ruggie Capital Group sold 2,000 Juno Therapeutics, Inc. shares in Q3 2017, an estimated $60K.
  • Ruggie Capital Group first reported a position in Juno Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Ruggie Capital Group's Juno Therapeutics, Inc. position peaked at $60K in Q2 2017.
  • 210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on Ruggie Capital Group's 13F filing for Q3 2017, filed 8 Nov 2017.